Showing 1921-1930 of 2002 results for "".
- ArteFill Changes Name to Bellafillhttps://practicaldermatology.com/news/artefill-changes-name-to-bellafill/2459051/Suneva Medical, Inc.’s ArteFill dermal filler has been rebranded as Bellafill in the US. "We feel that the brand Bellafill better embodies the transformational outcomes this unique product can provide to our customers and th
- FDA Approves Valeant's Onexton Gel for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-valeants-onexton-gel-for-the-treatment-of-acne-vulgaris/2459053/The FDA approved Valeant Pharmaceuticals International, Inc.’s Onexton Gel (clindamycin phosphate and benzoyl peroxide) 1.2%/3.75% for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older. "We are very pleased that the FDA has approved this new d
- DermSpectra Releases Total Body Digital Skin Imaging Systemhttps://practicaldermatology.com/news/dermspectra-releases-its-total-body-digital-skin-imaging-system/2459052/DermSpectra realease its DermSpectra Total Body Digital Skin Imaging System, which enables physicians to monitor critical skin changes (skin cancers, eczema, lesions, psoriasis, and rashes) over time. The DermSpectra advanced medical technology allows physicians to digitally capture and compare s
- Syneron Candela Expands Capabilities of UltraShape Platform, Receives FDA Clearance for the New U-Sculpt Transducer and Enhanced Ultrasound Powerhttps://practicaldermatology.com/news/20141117-syneron_candela_expands_capabilities_of_ultrashape_platform_receives_fda_clearance_for_the_new_u-sculpt_transducer_and_enhanced_ultrasound_power/2459064/The FDA cleared Syneron Medical Ltd.'s U-Sculpt transducer for the UltraShape non-invasive fat destruction platform. The FDA also cleared the V3.1 platform for a 25 percent increase in Ultrasound power in the new U-sculpt transducer and the previously cleared larger VDF transducer. This 25 percen
- Provectus ESMO Presentation: Ablative, Bystander Effects Of PV-10https://practicaldermatology.com/news/20140929-provectus_esmo_presentation_ablative_bystander_effects_of_pv-10/2459103/Provectus Biopharmaceuticals, Inc.'s data featured in a presentation during the European Society For Medical Oncology (ESMO) 2014 Congress in Madrid, Spain, show PV-10 has a higher rate of response in injected tumors through its ablative effect, and that the durability of response as well as the
- LEO Pharma and KLOX Technologies Strike Global Dermatology Dealhttps://practicaldermatology.com/news/20140715-leo_pharma_and_klox_technologies_strike_global_dermatology_deal/2459167/LEO Pharma A/S and KLOX Technologies Inc. have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize KLOX's BioPhotonic technology platform in dermatology, which includes a CE-approved treatment for moderate to sever
- Ultherapy Decolletage Treatment Now FDA Clearedhttps://practicaldermatology.com/news/20140707-ultherapy_dcolletage_treatment_now_fda_cleared/2459179/The FDA cleared Ulthera, Inc.'s Ulthera System for the non-invasive treatment of the chest to improve lines and wrinkles of the décolleté. The Ultherapy Décolletage Treatment uses the system's signature imaging and micro-focued ultr
- Allergan Reiterates its Belief that Valeant's Business Model is Unsustainablehttps://practicaldermatology.com/news/20140616-allergan_reiterates_its_belief_that_valeants_business_model_is_unsustainable/2459204/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today reiterated the Company's concern regarding Valeant Pharmaceuticals International, Inc.'s ("Valeant") unsustainable business model, which relies on serial acquisitions and cost reductions, as opposed to top-line revenue growth and operati
- Syneron Candela Achieves Approval to Market Its ALEX II System in Japanhttps://practicaldermatology.com/news/20140429-syneron_candela_achieves_approval_to_market_its_alex_ii_system_in_japan/2459250/Syneron Medical Ltd.'s subsidiary in Japan, Candela KK, received registration approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its ALEX II system in Japan for the treatment of benign dermal lesions.&nbs
- Presentation: PV-10 decreases Melanoma Cells in Tumors and Boosts T-Cellshttps://practicaldermatology.com/news/20140407-presentation_pv-10_decreases_melanoma_cells_in_tumors_and_boosts_t-cells/2459277/Treatment with Provectus Biopharmaceuticals, Inc.'s PV-10 produces a significant decrease in melanoma cells in tumors 7-14 days after treatment, new data show. The data were presented by researchers at the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Sa